Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?

The newer oral treatments for chronic hepatitis C virus infection are one of the greatest revolutions in modern medicine. These drugs promise to eradicate the infection, showing high cure rates even in difficult to treat populations with very few side effects. Nevertheless, some cases of recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Dias, Cátia, Duarte-Ribeiro, Filipa, Pipa, Sara, Barbosa, Ana Rita, Mota, Margarida, Rosas Vieira, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125765/
https://www.ncbi.nlm.nih.gov/pubmed/30191133
http://dx.doi.org/10.1016/j.idcr.2018.e00450
_version_ 1783353218240086016
author Dias, Cátia
Duarte-Ribeiro, Filipa
Pipa, Sara
Barbosa, Ana Rita
Mota, Margarida
Rosas Vieira, Fernando
author_facet Dias, Cátia
Duarte-Ribeiro, Filipa
Pipa, Sara
Barbosa, Ana Rita
Mota, Margarida
Rosas Vieira, Fernando
author_sort Dias, Cátia
collection PubMed
description The newer oral treatments for chronic hepatitis C virus infection are one of the greatest revolutions in modern medicine. These drugs promise to eradicate the infection, showing high cure rates even in difficult to treat populations with very few side effects. Nevertheless, some cases of recurrence and de novo hepatocellular carcinoma after treatment with these drugs have been reported. We describe two cases of patients treated with direct-acting antiviral agents that developed hepatocarcinoma during follow-up post-treatment.
format Online
Article
Text
id pubmed-6125765
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61257652018-09-06 Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk? Dias, Cátia Duarte-Ribeiro, Filipa Pipa, Sara Barbosa, Ana Rita Mota, Margarida Rosas Vieira, Fernando IDCases Article The newer oral treatments for chronic hepatitis C virus infection are one of the greatest revolutions in modern medicine. These drugs promise to eradicate the infection, showing high cure rates even in difficult to treat populations with very few side effects. Nevertheless, some cases of recurrence and de novo hepatocellular carcinoma after treatment with these drugs have been reported. We describe two cases of patients treated with direct-acting antiviral agents that developed hepatocarcinoma during follow-up post-treatment. Elsevier 2018-08-30 /pmc/articles/PMC6125765/ /pubmed/30191133 http://dx.doi.org/10.1016/j.idcr.2018.e00450 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Dias, Cátia
Duarte-Ribeiro, Filipa
Pipa, Sara
Barbosa, Ana Rita
Mota, Margarida
Rosas Vieira, Fernando
Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
title Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
title_full Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
title_fullStr Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
title_full_unstemmed Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
title_short Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
title_sort hepatocellular carcinoma after direct-acting antiviral therapy for chronic hcv infection: is it a real risk?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125765/
https://www.ncbi.nlm.nih.gov/pubmed/30191133
http://dx.doi.org/10.1016/j.idcr.2018.e00450
work_keys_str_mv AT diascatia hepatocellularcarcinomaafterdirectactingantiviraltherapyforchronichcvinfectionisitarealrisk
AT duarteribeirofilipa hepatocellularcarcinomaafterdirectactingantiviraltherapyforchronichcvinfectionisitarealrisk
AT pipasara hepatocellularcarcinomaafterdirectactingantiviraltherapyforchronichcvinfectionisitarealrisk
AT barbosaanarita hepatocellularcarcinomaafterdirectactingantiviraltherapyforchronichcvinfectionisitarealrisk
AT motamargarida hepatocellularcarcinomaafterdirectactingantiviraltherapyforchronichcvinfectionisitarealrisk
AT rosasvieirafernando hepatocellularcarcinomaafterdirectactingantiviraltherapyforchronichcvinfectionisitarealrisk

Ejemplares similares